New Drug Combo Potentially 'Practice Changing' in CLL Medscape NEW ORLEANS — More clinical details have been reported showing how the new monoclonal antibody obinutuzumab (Gazvya, Roche) was superior to the stadard therapy rituximab (Rituxan, Roche) when both were used in combination with chlorambucil in ... |
